Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions
Radiopharmaceutical therapy (RPT) has, in comparison to external-beam radiation therapy (EBRT), the unique advantage of addressing all tumor sites, including occult metastases. On the other hand, dose heterogeneity is the Achilles heel of RPT. Tumor-absorbed doses can vary widely between patients
Authors
- Elif Hindié (ORCID: https://orcid.org/0000-0003-2101-5626)
- Ravi B. Patel (ORCID: https://orcid.org/0000-0002-8328-746X)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Institut Universitaire de France (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Institut de Neurosciences Cognitives et Intégratives d’Aquitaine (FR)
- Bordeaux Population Health (FR)
- UPMC Hillman Cancer Center (US)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-03-27
- DOI
- https://doi.org/10.2967/jnumed.125.269644
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00